PFE - Pfizer Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
43.69
+0.18 (+0.41%)
As of 11:04AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close43.51
Open43.62
Bid43.78 x 1400
Ask43.78 x 800
Day's Range43.51 - 43.94
52 Week Range33.20 - 45.81
Volume4,103,198
Avg. Volume21,821,709
Market Cap252.549B
Beta (3Y Monthly)0.73
PE Ratio (TTM)11.04
EPS (TTM)3.96
Earnings DateJan 28, 2019 - Feb 1, 2019
Forward Dividend & Yield1.36 (3.13%)
Ex-Dividend Date2018-11-08
1y Target Est43.79
Trade prices are not sourced from all markets
  • Final Trades: Virtu, JPMorgan & Pfizer
    CNBC Videos3 days ago

    Final Trades: Virtu, JPMorgan & Pfizer

    The "Halftime Report" traders give their top stocks to watch for the second half.

  • MARKETS: Stocks could bounce here, but I'm selling the rally
    Yahoo Finance Video4 days ago

    MARKETS: Stocks could bounce here, but I'm selling the rally

    Risk markets continue to deliver mixed messages to traders and market participants. The latest price action suggests more downside -- but first -- with a possible bounce to the 2750 level in the S&P 500, says Yahoo Finance's Jared Blikre, who breaks it down with Jen Rogers and Myles Udland.

  • Amgen's Blincyto Gets Positive CHMP Opinion for Line Extension
    Zacks1 hour ago

    Amgen's Blincyto Gets Positive CHMP Opinion for Line Extension

    Amgen's (AMGN) leukemia drug, Blincyto receives positive CHMP opinion for label expansion to include minimal residual disease.

  • Investing.com38 minutes ago

    Stocks - Apple Falls in Pre-market; Nissan, Renault, PG&E, JD.com Sink

    Investing.com - Stocks in focus in pre-market trade Monday:

  • Drug Pricing Resurfaces, Pfizer to Raise Cost of 41 Drugs
    Zacks1 hour ago

    Drug Pricing Resurfaces, Pfizer to Raise Cost of 41 Drugs

    Per a Wall Street report, Pfizer (PFE) plans to increase the list prices of its 41 prescription drugs in 2019.

  • TheStreet.com2 hours ago

    Pfizer Could Rally in the Weeks Ahead as Investors Look Beyond Today's Headline

    Market watchers and analysts are waiting for a tweet from President Trump to try to embarrass or strong arm management into rescinding the raises. The rising On-Balance-Volume (OBV) is positive until early October and then it turns neutral/positive. Prices dip in October/November but the OBV line has been steady/flat telling me that buyers and sellers of PFE have been balanced.

  • TheStreet.com2 hours ago

    Pfizer Stock Slides Slightly as Drug-Maker Prepares Price Increases

    drug price increases that defy the oval office are provoking a mixed response. Shares of the New York City-based pharmaceutical giant have remained largely flat to slightly negative in pre-market, adding further signs of uncertainty to what has been a tumultuous fourth quarter so far amid pressure from both President Trump and HHS Secretary Alex Azar on the pricing issue. The company's announcement of price increases comes shortly after HHS Secretary Azar discussed problems with transparency and pricing controls in the industry.

  • How Is Bausch Health’s Ortho Dermatologics Performing?
    Market Realist2 hours ago

    How Is Bausch Health’s Ortho Dermatologics Performing?

    Bausch Health’s (BHC) wholly owned subsidiary Ortho Dermatologics generated revenues of $177.0 million in the third quarter. In the third quarter, Ortho Dermatologics’ net revenues remained flat compared to the third quarter of 2017. Ortho Dermatologics witnessed ~1% YoY organic revenue growth.

  • The Zacks Analyst Blog Highlights: Pfizer, Cisco, Southern, SunTrust Banks and AmerisourceBergen
    Zacks3 hours ago

    The Zacks Analyst Blog Highlights: Pfizer, Cisco, Southern, SunTrust Banks and AmerisourceBergen

    The Zacks Analyst Blog Highlights: Pfizer, Cisco, Southern, SunTrust Banks and AmerisourceBergen

  • MarketWatch3 hours ago

    Merck KGaA and Pfizer say drug failed to meet primary endpoints in late-stage ovarian cancer trial

    Merck KGaA and Pfizer Inc. said early Monday that the cancer immunotherapy avelumab did not meet the primary endpoints of a phase 3 ovarian cancer trial. The trial, JAVELIN Ovarian 200, tested avelumab both alone and in combination with chemotherapy. It specifically focused on individuals with platinum-resistant or -refractory ovarian cancer, or cancers that did not respond to prior chemotherapy treatment, "a population known to have disease that is challenging to treat; as such, this group of patients in typically not included in Phase 3 ovarian cancer trials," Dr. Chris Boshoff, Pfizer's senior vice president and head of immuno-Oncology, early development and translational oncology, said. "The results speak to the significant challenges these women face." Another Merck and Pfizer trial of avelumab, in a type of lung cancer, also did not meet its primary endpoint earlier this year. The drug is being tested in several other types of cancer, with roughly 17 total clinical trials ongoing, according to Pfizer's drug pipeline. Both U.S.-listed Merck KGaA and Pfizer shares were inactive in Monday premarket trade. Merck KGaA shares have surged 8.8% over the last three months and Pfizer shares have risen 3.4%, compared with a nearly 4% drop in the S&P 500 and a 1% decline in the Dow Jones Industrial Average .

  • PR Newswire4 hours ago

    Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

    DARMSTADT, Germany and NEW YORK , November 19, 2018 /PRNewswire/ -- Not intended for UK-based media     Merck KGaA, Darmstadt, Germany , and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN ...

  • ACCESSWIRE4 hours ago

    Today's Research Reports on Trending Tickers: Facebook and Pfizer

    NEW YORK, NY / ACCESSWIRE / November 19, 2018 / Pfizer and Facebook were both in deep water last week. Pharma giant Pfizer decided to increase the prices of 41 drugs according to the WSJ with the price hikes taking effect in January. Shares of Facebook hit a new low as Wall Street continued to grapple with a NY Times article about executives at the company ignoring warning signs of abuse.

  • TheStreet.com5 hours ago

    Carlos Ghosn, Apple, US-China Trade, Bitcoin and Pfizer - 5 Things You Must Know

    shares plunged to the lowest level in four years Monday, wiping more than $2 billion from the company's market value, after Nissan Motor Co. said chairman Carlos Ghosn misused company funds following an investigation in cooperation with Japan's Public Prosecutors Office. The Nissan statement followed a a report from Japan's Asahi newspaper, and other media outlets, that the Renault CEO faces arrest for allegedly violating the country's financial instruments and exchange linked to his role as chairman of Nissan Motor Co.

  • Where Will Pfizer Inc. Be in 5 Years?
    Motley Fool2 days ago

    Where Will Pfizer Inc. Be in 5 Years?

    A peek into the likely future for the big drugmaker.

  • TheStreet.com2 days ago

    Pfizer Plans Price Hikes for 41 Drugs Next Year

    said Friday, Nov. 16, it plans to increase list prices for 41 of its drugs effective Jan. 15. The plan was first reported by The Wall Street Journal. "The only exceptions are three products that have a 3% increase and one product that is increasing 9% due to the completion of two extensive development programs that have led to the recent FDA approvals of two new medical uses that meet unmet patient needs," Pfizer said.

  • The Wall Street Journal3 days ago

    [$$] Pfizer to Raise Prices on 41 Drugs in January

    Pfizer Inc. plans to resume its practice of raising drug prices early next year after bowing to pressure from President Trump over the summer when the company rolled back some increases. Pfizer, among the world’s biggest drugmakers by sales, won’t be raising prices as much as it has in past years. It said it would raise the list prices of 41 of its prescription drugs, or 10% of its portfolio, in January.

  • Reuters3 days ago

    Pfizer to raise US drug prices in January after previously backing down

    Pfizer Inc said on Friday that it plans to hike U.S. prices on 41 of its medicines in January, after walking back its previous planned price increases this summer under pressure from President Donald Trump. Pfizer said it would raise the list price of most of the drugs by 5 percent, while prices for three will rise by 3 percent, and the price of one by 9 percent, all effective Jan. 15. Pfizer said it does not expect the price increases to boost its revenue in the United States next year as it believes that rebates to insurance companies and pharmacy benefit managers (PBMs) will offset them.

  • Pfizer to raise drug prices in January
    American City Business Journals3 days ago

    Pfizer to raise drug prices in January

    Pfizer plans to raise the list prices of 41 of its prescription drugs, or 10 percent of its portfolio, in January. According to The Wall Street Journal, citing an unnamed source, most of the planned increases will be 5 percent, while three of the drugs’ list prices will go up by 3 percent. One of the drug prices will go up by 9 percent, the report continued.

  • MarketWatch3 days ago

    Pfizer to raise prices on 41 drugs: report

    Pfizer plans to raise the list prices of 41 of its prescription drugs, or 10% of its portfolio, in January, The Wall Street Journal reported Friday, citing a person familiar with the matter. Most of the increases will be around 5% and would take effect Jan. 15, the person said, according to the WSJ. Pfizer rolled back some increases in July under criticism from President Donald Trump, but earlier this month Chief Executive Ian Read said Pfizer was likely to go back to price hikes in January. Shares of Pfizer rose 0.1% in the extended session Friday after ending the regular trading day up 0.7%.

  • CNBC3 days ago

    Pfizer to raise prices on 41 prescription drugs next year despite pressure from Trump

    Pfizer will raise list prices on 41 prescription drugs in January. Pfizer this summer deferred planned price increases after President Donald Trump criticized the drug giant. Trump said Pfizer and other drugmakers "should be ashamed" of themselves.

  • Reuters3 days ago

    Pfizer plans to increase U.S. drug prices in January

    Pfizer Inc said on Friday that it plans to hike U.S. prices on 41 of its medicines in January, after walking back its previous price increases this summer under pressure from President Donald Trump. Pfizer said it would raise the price of most of the drugs by 5 percent, while prices for three will rise by 3 percent, and the price of one other will rise by 9 percent.

  • AstraZeneca Shows It Can Still Take Some Knocks
    Bloomberg3 days ago

    AstraZeneca Shows It Can Still Take Some Knocks

    On Friday, the company said Imfinzi, its key lung cancer drug, had failed to deliver significant survival rates in late-stage, non-small cell lung cancer when used in combination with another of its immuno-oncology treatments. Rewind four years, and immuno-oncology – which enhances the body’s own ability to fight cancer – was a central pillar of Soriot’s defense. Concern about this pairing's performance in tests is one reason why it has taken until this year for AstraZeneca shares to climb above the 55 pounds-a-share proposal from Pfizer and stay there.

  • Financial Times3 days ago

    [$$] Pfizer to raise prices for 41 drugs despite Trump criticism

    Pfizer said it would increase the price of 41 products in its drug portfolio, just four months after having initially put off those plans amid heavy criticism from US President Donald Trump. — after Mr Trump said it should be “ashamed” of the move and that it and other rivals were “taking advantage of poor people”. Effective January 15, 2019, prices for 37 of the products will rise by 5 per cent, while three products will see prices rise by 3 per cent, and one by 9 per cent.

  • Sangamo's Shares Drop on Rating Downgrade, Pipeline Woes
    Zacks4 days ago

    Sangamo's Shares Drop on Rating Downgrade, Pipeline Woes

    Sangamo Therapeutics (SGMO) postpones data presentation from its haemophilia study, following dose escalation recommendation from an independent committee. This raises concerns about its development.